Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies - Fig 5
- Holly Koblish (5435765)
- Yun-long Li (5435738)
- Niu Shin (2245552)
- Leslie Hall (5435756)
- Qian Wang (32718)
- Kathy Wang (5435741)
- Maryanne Covington (2139592)
- Cindy Marando (68644)
- Kevin Bowman (5435744)
- Jason Boer (5435759)
- Krista Burke (5435747)
- Richard Wynn (2332183)
- Alex Margulis (5435762)
- Gary W. Reuther (333463)
- Que T. Lambert (5435753)
- Valerie Dostalik Roman (5435750)
- Ke Zhang (115386)
- Hao Feng (54208)
- Chu-Biao Xue (2139553)
- Sharon Diamond (2139568)
- Greg Hollis (2139547)
- Swamy Yeleswaram (2139574)
- Wenqing Yao (314606)
- Reid Huber (2666968)
- Kris Vaddi (2139544)
- Peggy Scherle (2139556)
Publication date
June 2018
DOIAbstract
<p><b>INCB053914 inhibits the phosphorylation of BAD in mice bearing MOLM-16 (AML) (A) or KMS-12 (MM) tumors (B), and inhibits growth of MOLM-16 (AML) (C) and KMS-12 (MM) (D) tumors <i>in vivo</i>. Mean INCB053914 plasma concentrations were determined at 2, 4, 8, and 16 hours post oral administration in mice bearing MOLM-16 tumors (E) or KMS-12-BM tumors (F).</b> EC<sub>50</sub> values for pBAD inhibition were determined by fitting data to a sigmoidal dose–response (variable slope) curve. Error bars represent standard error of the mean. BID, twice a day; PO, orally.</p
Add to ORKG